Insider Transactions in Q4 2021 at Blueprint Medicines Corp (BPMC)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
729
-2.71%
|
$72,900
$100.0 P/Share
|
|
Dec 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+2.64%
|
$48,114
$66.24 P/Share
|
|
Dec 13
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-0.46%
|
$98,000
$98.13 P/Share
|
|
Dec 13
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Dec 08
2021
|
Tango Therapeutics, Inc. Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+50.0%
|
-
|
|
Dec 07
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-4.41%
|
$480,000
$96.46 P/Share
|
|
Dec 07
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.51%
|
$140,000
$28.36 P/Share
|
|
Nov 16
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,950
-16.19%
|
$222,300
$114.28 P/Share
|
|
Nov 16
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,950
+5.4%
|
$15,600
$8.56 P/Share
|
|
Nov 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
729
-2.71%
|
$83,835
$115.49 P/Share
|
|
Nov 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+2.64%
|
$48,114
$66.24 P/Share
|
|
Nov 15
2021
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
30,000
-3.54%
|
$3,390,000
$113.51 P/Share
|
|
Nov 15
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.51%
|
$240,000
$8.44 P/Share
|
|
Nov 03
2021
|
Christina Rossi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
511
-1.15%
|
$56,210
$110.85 P/Share
|
|
Nov 03
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-6.66%
|
$550,000
$110.18 P/Share
|
|
Nov 03
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.55%
|
$140,000
$28.36 P/Share
|
|
Nov 01
2021
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-2.58%
|
$575,000
$115.16 P/Share
|
|
Nov 01
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.52%
|
$75,000
$15.01 P/Share
|
|
Nov 01
2021
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
SELL
Open market or private sale
|
Direct |
5,177
-5.04%
|
$579,824
$112.91 P/Share
|
|
Nov 01
2021
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,177
+6.91%
|
$139,779
$27.03 P/Share
|
|
Oct 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
729
-2.71%
|
$74,358
$102.66 P/Share
|
|
Oct 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+2.64%
|
$48,114
$66.24 P/Share
|
|
Oct 05
2021
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
3,241
-7.11%
|
$317,618
$98.18 P/Share
|